BUDAPEST, Hungary, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company is presenting an overview of results for its patented Vaxfectin® adjuvant at the Modern Veterinary Vaccines & Adjuvants conference (Budapest, Hungary, November 17 – 19). Vaxfectin® has demonstrated promising results in a broad range of animal studies in infectious disease and cancer vaccine applications including DNA, protein and peptide vaccines, as well as initial human studies with pandemic influenza DNA vaccines. The company is exploring international partnering opportunities for veterinary applications of its technologies to supplement its existing pipeline of independent and collaborative programs.
